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Objective. Sclerostin is a Wnt inhibitor produced specifically by osteocytes. However, it is not currently clear whether renal
dysfunction has an effect on circulating sclerostin level in patients with type 2 diabetes. The aim of the study was to evaluate this
relationship.Design and Patients.We conducted a cross-sectional observational study of 302 type 2 diabetic patients with or without
chronic kidney disease. Serum sclerostin level was analyzed by ELISA, and renal function was assessed by estimated glomerular
filtration rate (eGFR) using chronic kidney disease epidemiology collaboration (CKD-EPI) equation. Results. There was a strong
correlation between sclerostin level with renal function presented as serum creatinine (𝑟 = 0.745,𝑃 < 0.001) and eGFR (𝑟 = −0.590,
𝑃 < 0.001). Serum sclerostin level was significantly higher in patients with CKD-G3 stage than those with CKD-G1/2 stages after
adjusting for age, sex, andBMI (𝑃 = 0.011). PatientswithCKD-G4/5 stages haddramatically increased level of circulating sclerostin.
Multiple regression analyses found that age, sex, and eGFR were independent determining factors for circulating sclerostin level.
Conclusion. Our data showed that serum sclerostin levels start to increase in diabetic patients with CKD-G3 stage. Further studies
are needed to establish the potential role of elevated sclerostin in diabetic patients with CKD.
1. Introduction
Sclerostin is a glycoprotein secreted almost exclusively by
osteocytes. It negatively regulates bone formation by binding
to low-density lipoprotein receptor-related proteins (LRPs)
5/6 and by antagonizing the Wnt/𝛽-catenin signaling path-
way [1–3]. Circulating sclerostin concentration has been
found to be higher in men than in women [4]. Sclerostin
concentration positively correlates with age, bodymass index
(BMI), and bone mineral density (BMD) [5]. Recent report
showed that diabetic patients had higher sclerostin level than
nondiabetic subjects [6].
There are few data regarding the effects of liver or
kidney function on serum sclerostin level. Previously, we
reported that sclerostin level was higher in patients with
liver cirrhosis than in healthy controls and correlated with
markers of liver dysfunction such as albumin [7].With regard
to renal function, Cejka et al. [8] found that patients with
chronic kidney disease (CKD) stage 5 on dialysis had higher
sclerostin levels than those without CKD and suggested
elevated sclerostin may play a role in renal osteodystrophy.
Also, recent report found that serum sclerostin levels increase
as estimated glomerular filtration rate (eGFR) decreases in
patients with CKD [9].
However, so far it was unknown whether this finding
applies to the patients with type 2 diabetes. In the present
study, we assessed serum sclerostin level according to renal
function in patients with type 2 diabetes.
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2. Patients and Methods
2.1. Study Population. Our study was a cross-sectional study
that included type 2 diabetic patients with or without CKD.
A total of 302 diabetic men and women who visited the
endocrinology or nephrology clinic were recruited from
Myongji Hospital or Severance Hospital from March 2010 to
September 2011. The study was approved by the Institutional
Review Board of Kwandong University College of Medicine
or Yonsei University College of Medicine. All the patients in
the study provided written informed consent.
2.2. Laboratory Measurements. Samples of venous blood
were taken in the morning after fasting overnight. Sera were
stored at −80∘C until examination. Fasting plasma glucose,
glycated hemoglobin (HbA1C),AST,ALT, and creatinine (Cr)
were measured using standard automated laboratory tech-
niques. Estimated glomerular filtration rate (eGFR) was cal-
culated using chronic kidney disease epidemiology collabo-
ration (CKD-EPI) creatinine equation. Patients were divided
into three groups by CKD stages according to decreased
degrees of GFR (CKD-G1/2, G3, and G4/5 stages). Subjects
with eGFR greater than 90mL/min/1.73m2 were categorized
as CKD-G1. G2 denotes eGFR 60∼89mL/min, G3 30∼
59mL/min, G4 15∼29mL/min, and G5 < 15mL/min/1.73m2.
Serum sclerostinwasmeasured using a quantitative sandwich
ELISA method (Biomedica Co., Vienna, Austria). The intra-
assay and interassay coefficients of variations (CVs) were
4–6% and 5–7%, respectively. Serum intact parathyroid
hormone (PTH) was measured by immunoradiometric assay
(Biosource, Nivelles, Belgium, with an intra-assay CV 2.7%
and interassay CV 3.5%).
2.3. Statistical Analysis. Statistical analysis was performed
with SPSS version 11.0. The values were presented as mean
± SD or median and interquartile range (Table 1) or mean
± SE (Figure 1). Pearson correlation analysis was used to
assess the correlations between serum sclerostin and other
parameters. We performed multivariate linear regression
analysis to investigate the association between eGFR and
serum sclerostin. Age, sex, BMI, HbA1C, serum calcium,
phosphorus, PTH, and duration of diabetes were included
in regression analysis. Univariate analysis of covariance
(ANCOVA) was used to evaluate the differences of sclerostin
level in men and women between the different CKD groups
after adjusting for age, sex, and BMI. A P value < 0.05 was
considered statistically significant.
3. Results
3.1. Characteristics of the Study Patients. The clinical and
biochemical characteristics of the study patients are shown
in Table 1. The average age was 67.4 ± 7.3 years, with a range
of 50–88. The mean eGFR was 53.9 ± 26.8mL/min/1.73m2.
Median sclerostin level was 64.4 pmol/L (interquartile range
45.4–91.1).
Forty-nine percent of patients had eGFR ≥60, 30%

























∗Age, sex, and BMI adjusted P = 0.011 versus G1/2
∗∗Age, sex, and BMI adjusted P < 0.001 versus G1/2 and G3
Figure 1: Serum sclerostin levels according to CKD groups in
patients with type 2 diabetes. Values are expressed as mean ± SE.
Table 1: Clinical and biochemical characteristics of patients (𝑛 =
302).
Characteristics Values
Age (years) 67.4 ± 7.3
Men/women (𝑛/𝑛) 143/159
Body mass index (kg/m2) 24.8 ± 3.1
Duration of diabetes (years) 14.6 ± 9.1
Fasting glucose (mg/dL) 151.4 ± 59.4
HbA1C (%) 7.6 ± 1.4
Aspartate transaminase (mg/dL) 23.2 ± 11.5
Alanine transaminase (mg/dL) 21.4 ± 13.7
Serum calcium (mg/dL) [𝑛 = 174] 9.2 ± 0.6
Serum phosphorus (mg/dL) [𝑛 = 174] 4.0 ± 0.9
Parathyroid hormone (pg/mL) [𝑛 = 114] 52.9 [27.5–170.8]
25(OH)D (ng/dL) 35.5 ± 22.7
Serum creatinine (mg/dL) 2.3 ± 2.9
Serum sclerostin (pmol/L) 64.4 [45.4–91.1]
eGFR (ml/min/1.73m2) 53.9 ± 26.8
CKD-eGFR categories
G1/2 (≥60ml/min/1.73m2) 149 (49.3%)
G3 (30∼59ml/min/1.73m2) 90 (29.8%)
G4/5 (<30ml/min/1.73m2) 63 (20.9%)
Data are shown asmean± SD ormedian [interquartile range] as appropriate.
(Table 1). Men had significantly higher sclerostin levels than
women after adjusting for age, BMI, and eGFR (121.4 ± 6.8
versus 76.1 ± 6.5 pmol/L, 𝑃 < 0.001).
3.2. Correlation of Serum Sclerostin with Renal Function.
Patients were classified into three groups according to their
eGFR categories (G1/2 versus G3 versus G4/5). We com-
pared serum sclerostin levels according to the groups using
ANCOVA. Serum sclerostin level was significantly higher in
patients with G4/5 or G3 than those with G1/2 after adjusting
for age, sex, and BMI (225.5 ± 10.9 versus 84.9 ± 9.2 versus
54.6 ± 6.9 pmol/L) (Figure 1).
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Table 2: Univariate correlations between serum sclerostin level and various parameters.
Variables Group with CKD-G1/2 Group with CKD-G3∼5 Total group
r P value r P value r P value
Age 0.031 0.711 −0.219 0.007 −0.048 0.403
Male sex 0.481 <0.001 0.211 0.009 0.158 0.006
Body mass index 0.213 0.009 −0.240 0.004 −0.157 0.007
HbA1C −0.244 0.005 −0.162 0.108 −0.129 0.051
Duration of diabetes 0.019 0.834 0.389 <0.001 0.381 <0.001
Serum creatinine 0.526 <0.001 0.708 <0.001 0.745 <0.001
eGFR −0.219 0.007 −0.574 <0.001 −0.590 <0.001
Calcium 0.051 0.662 −0.302 0.002 −0.343 <0.001
Phosphorus −0.049 0.679 0.391 <0.001 0.452 <0.001
PTH −0.265 0.136 0.383 <0.001 0.485 <0.001
Table 3: Multiple regression analysis to identify factors associated with serum sclerostin level.
Variables Group with CKD-G1/2 Group with CKD-G3∼5 Total group








Age 0.010 0.958 −0.205 0.035 −0.214 0.004
Male sex 0.506 0.009 0.240 0.004 0.172 0.008
Body mass index 0.224 0.296 −0.196 0.033 −0.135 0.074
HbA1C −0.257 0.164 −0.065 0.385 −0.026 −0.415
Duration of diabetes 0.003 0.987 −0.042 0.621 −0.069 0.372
Calcium 0.146 0.796 −0.002 0.983 −0.118 0.128
Phosphorus 0.128 0.474 0.066 0.517 0.153 0.059
PTH −0.279 0.112 −0.193 0.141 0.058 0.577
eGFR −0.166 0.435 −0.868 <0.001 −0.659 <0.001
There was a strong correlation between sclerostin level
and renal function, presented as serum Cr and eGFR in
the entire cohort (Cr; 𝑟 = 0.745, eGFR; 𝑟 = −0.590,
resp., 𝑃 < 0.001) (Table 2). Multiple regression analysis
showed that eGFRwas an independent determining factor for
circulating sclerostin level in the entire cohort (standardized
beta coefficients = −0.659, 95% CI −4.8, −2.4) (Table 3).
3.3. Correlation between Serum Sclerostin, PTH, Calcium,
and Phosphate. Serum PTH was measured only in a small
proportion of the subjects (𝑛 = 114). Univariate analysis
showed positive correlation of PTH with serum sclerostin
in the entire cohort or patients with CKD-G3∼5. However,
serum sclerostinwas not correlatedwith PTH in patientswith
CKD-G1/2 (Table 2). Multiple regression analysis found that
PTH was not an independent factor for serum sclerostin in
the entire cohort or CKD subgroups.
Univariate analysis revealed that there were significant
correlations between serum sclerostin and phosphate (𝑟 =
0.452, 𝑃 < 0.001) or calcium (𝑟 = −0.343, 𝑃 < 0.001) in the
entire cohort, but these relationships disappeared in patients
with G1/2 (𝑟 = −0.049, 𝑃 = 0.679 for phosphate, 𝑟 = 0.051,
𝑃 = 0.662 for calcium).There was a weak positive correlation
between serum phosphate and sclerostin in the entire cohort
(𝛽 = 0.153, 𝑃 = 0.059), which did not persist when different
CKD groups (𝛽 = 0.128, 𝑃 = 0.474 for CKD-G1/2 group,
𝛽 = 0.066, 𝑃 = 0.517 for CKD-G3∼5 group) were analyzed
separately in the multiple regression analysis.
3.4. Correlation of Serum Sclerostin with BMI and Duration
of Diabetes. BMI showed negative correlation with serum
sclerostin in all patients (𝑟 = −0.157, 𝑃 = 0.007), but it
positively correlated with sclerostin in patients with G1/2 (𝑟 =
0.213, 𝑃 = 0.009) (Table 2). The negative correlation of BMI
with sclerostin only remained in patients with CKD-G3∼5
after multivariate analysis (𝑟 = −0.196, 𝑝 = 0.033) (Table 3).
Duration of diabetes significantly and positively was
correlated with serum sclerostin in the entire cohort (𝑟 =
0.381, 𝑃 < 0.001) (Table 2). However, duration of diabetes
was not an independent factor for circulating sclerostin in
multiple regression analysis (𝛽 = −0.069, 𝑃 = 0.372).
Multiple regression analysis has shown that eGFR, age, and
sex were independently associated with serum sclerostin in
the entire cohort (Table 3).
4. Discussion
This cross-sectional study found that circulating sclerostin
level was significantly higher in type 2 diabetic patients with
CKD-G3 or G4/5 stage than those with G1/2 stage. Also, we
found that eGFR, age, and sex were independently associated
with circulating sclerostin.
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Previously, Cejka et al. found that patientswithCKDstage
5 on dialysis showed higher sclerostin levels than patients
without CKD (2055 ± 1239 pg/mL in CKD 5 patients on
dialysis; 480 ± 150 pg/mL in premenopausal women; 1160 ±
380 pg/mL in postmenopausal women) [8, 10].They reported
that sclerostin showed a significant negative association with
parameters of bone turnover such as activation frequency
and bone formation rate (BFR)/bone surface (BS) in stage
5D CKD patients. They also found a significant association
between sclerostin and osteoblast number [8].
Our study found serum sclerostin levels were 1.5 times
higher in diabetic patients with CKD-G3 stage than in those
with G1/2 after adjusting for age, sex, and BMI. Moreover,
serum sclerostin levels were 4 times higher in patients with
CKD-G4/5 stage compared with those with G1/2. Our results
were consistent with the recent report by Sabbagh et al. [11].
They reported that repression of osteocytes Wnt/𝛽-catenin
signaling and increased expression of sclerostin occurred in
early stage of CKD in a geneticmodel ofmice.They suggested
that repression of theWnt/𝛽-catenin pathway is an early event
in the progression of renal osteodystrophy. Interestingly,
recent report found that increased sclerostin levels in CKD
patients were not due to decreased renal elimination. On
the contrary, increased circulating sclerostin is the result of
increased sclerostin production in uremic patients [12]. The
mechanisms underlying increased production of sclerostin in
CKD are yet unknown. Our results and recent other reports
suggest that higher circulating sclerostin due to increased
production might have a role of decreased bone quality in
diabetic patients with early CKD.
The effects of PTH on bone are mediated, at least partly,
through inhibition of sclerostin expression [10, 13–15]. Many
studies, but not all, have shown inverse correlation between
serum sclerostin and PTH level [8, 10, 15–17]. Mirza et al. [10]
reported that serum sclerostin levels negatively correlated
with PTH in postmenopausal women without CKD. Cejka
et al. [8] also showed significant inverse correlation between
sclerostin and PTH in 60 patients with stage 5 CKD on
dialysis. Our study found that there was a positive correlation
between sclerostin and PTH in the univariate analysis of
the entire cohort or patients with CKD-G3∼5, although this
correlation did not persist in the multiple regression analysis.
The cause of inconsistent results between our study and other
reports is unknown. One possibility is that renal failure leads
to skeletal resistance to PTH, and decreases in PTH signalling
activity might result in increased production of sclerostin
in CKD patients. Another explanation is that as the major
determinant of serum PTH and sclerostin is GFR this might
have largely overridden the results in the present study.
With regard to correlation of serum phosphate with
sclerostin, few reports and results are conflicting so far.
Pelletier and colleagues [9] reported that serum phosphate
was independently associated with sclerostin level in 90
adult patients with CKD. Recent report found that dietary
phosphate stimulated bone sclerostin expression indepen-
dently of PTH in a model of CKD-adynamic bone disease
(ABD) [18]. On the other hand, Cejka et al. [12] reported
that there was no association between serum sclerostin and
fractional excretion of phosphate in a multivariate analysis.
They suggested that rises in phosphate and sclerostin levels
in CKD patients occur simultaneously but are not necessarily
mechanistically linked. In the present study, there was a
weak correlation between serum phosphate and sclerostin
in the entire cohort (𝑃 = 0.059), which did not persist
when different CKD groups were analyzed separately in the
multiple regression analysis.
We found that serum sclerostin was significantly associ-
ated with duration of diabetes or HbA1C in the univariate
analysis. However, they were not independent factors for
circulating sclerostin in the multiple regression analysis.
Our results are inconsistent with previous report by Garcia-
Martin et al. [6]. They reported that serum sclerostin was
correlatedwith duration of diabetes and glycated hemoglobin
in patients with type 2 diabetes. However, they adjusted for
only age to investigate the association between duration of
diabetes and sclerostin. In the present study, serum sclerostin
was significantly associated with duration of diabetes after
adjusting for age, sex, and eGFR (𝛽 = 0.192, 𝑃 < 0.001,
data not shown), which disappeared after adjusting further
confounders.
We also observed that men had significantly higher
sclerostin levels than women after adjusting for age, BMI,
and renal function. This finding is consistent with previous
data from other groups. Mo¨dder et al. [4] reported that men
had higher circulating sclerostin levels than women in a
population-based sample. Kirmani et al. [19] demonstrated
that serum sclerostin levels were higher in boys aged 6–21
years, compared with girls of the same age range. They sug-
gested that the gender difference in sclerostin level appears to
be established during puberty. Another group found that age
and serum estradiol (E2) levels were determinants of serum
sclerostin level in healthy pre- and postmenopausal women
[20]. Therefore, it is plausible that lower estrogen level as
well as a larger skeleton may explain the higher circulating
sclerostin level in men compared with women. However,
recent observational study did not find any difference on
sclerostin level between men and women after adjusting for
age, bone mineral content, physical activity, BMI, and renal
function [5].The reason for these different results is not clear.
With regard to age, Ardawi et al. [20] reported that serum
sclerostin level increases significantly with age in healthy pre-
and postmenopausal women. Serum sclerostin level increases
over life by an average of 3.7-fold (𝑃 < 0.0001). They
suggested that increased sclerostin production by osteocytes
may be involved in the age-related impairment of bone
formation. Intriguingly, age was negatively correlated with
serum sclerostin in the multiple regression analysis of our
study. We cannot explain the reason, but it is possible that
our study subjects had wide range of renal function including
CKD5 and renal function acts as a strong determining factor
on circulating sclerostin level, which leads to having an effect
on the relationship between sclerostin and age.
This study has several limitations. First, this is a cross-
sectional observational study that demonstrated associations,
not causal relationships. Second, serum PTH levels were
measured in a small proportion of study patients and may
affect the statistical power of our study. Therefore, we tried
to overcome this by adding PTH to the multivariate analysis.
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In conclusion, we have shown that circulating sclerostin
level negatively correlated with eGFR in diabetes patients
with wide range of renal function. Also, serum sclerostin
levels start to increase in diabetic patients with CKD-G3
stage. Further, studies are needed to establish the potential
role of elevated sclerostin in diabetic patients with early CKD.
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